Philip Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip Chang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Chawnshang Chang
George Whipple Lab for Cancer Research, Departments of Pathology and Urology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, USA
3 shared publications - Colleen M. Ryan
Shriners Children’s- Boston , Boston, MA
2 shared publications Ilana Ruff
From the Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL
2 shared publicationsJiann-Jyh Lai
George Whipple Lab for Cancer Research, Departments of Pathology and Urology and The Wilmot Cancer Center, University of Rochester Medical Center, Box 626, URMC, 601 Elmwood Ave, Rochester, NY 14642, USA
2 shared publicationsKuo-Pao Lai
George Whipple Lab for Cancer Research, Departments of Pathology and Urology and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, USA
2 shared publicationsShuyuan Yeh
Urology and Departments of
2 shared publications
Latest Publications
- 22 September 2020
- Published by SAGE Publications in The Neurohospitalist
- Vol. 11  (2) , 152-155
A Post-Infectious Steroid-Responsive Brainstem Lesion Associated With COVID-19
A 51-year-old man developed coma, bilateral pupillary dilation, ophthalmoplegia and quadriplegia 4 weeks after testing positive for COVID-19. MRI demonstrated a symmetric midline pontine non-enhancing T2-FLAIR hyperintense lesion. The patient was treated with intravenous methylprednisolone, which resulted in improvement of his Glasgow Coma Scale (GCS) from 3 to 15 over the next 5 days. To our knowledge, this is the first case of a post-infectious steroid-responsive brainstem lesion associated with COVID-19. The clinical picture best fits in the family of a steroid-responsive encephalopathy and reminds us that COVID-19 may cause severe post-infectious neurological complications.
- 22 September 2020
- Published by SAGE Publications in The Neurohospitalist
- Vol. 11  (2) , 152-155
A Post-Infectious Steroid-Responsive Brainstem Lesion Associated With COVID-19
A 51-year-old man developed coma, bilateral pupillary dilation, ophthalmoplegia and quadriplegia 4 weeks after testing positive for COVID-19. MRI demonstrated a symmetric midline pontine non-enhancing T2-FLAIR hyperintense lesion. The patient was treated with intravenous methylprednisolone, which resulted in improvement of his Glasgow Coma Scale (GCS) from 3 to 15 over the next 5 days. To our knowledge, this is the first case of a post-infectious steroid-responsive brainstem lesion associated with COVID-19. The clinical picture best fits in the family of a steroid-responsive encephalopathy and reminds us that COVID-19 may cause severe post-infectious neurological complications.
- Open Access
- 1 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11  (1) , 1-14
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
The antiandrogen enzalutamide (Enz) has improved survival in castration resistant prostate cancer (CRPC) patients. However, most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection in CRPC patients following Enz treatment. Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo. Our findings suggest that Enz-increased ARv7 expression can transcriptionally enhance MAO-A expression resulting in Enz resistance via altering the hypoxia HIF-1α signals. Together, our results show that targeting the Enz/ARv7/MAO-A signaling with the antidepressants phenelzine or clorgyline can restore Enz sensitivity to suppress EnzR cell growth, which may indicate that these antidepression drugs can overcome the Enz resistance to further suppress the EnzR CRPC.
- 1 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11  (1) , 1-14
Open AccessThe MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
The antiandrogen enzalutamide (Enz) has improved survival in castration resistant prostate cancer (CRPC) patients. However, most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection in CRPC patients following Enz treatment. Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo. Our findings suggest that Enz-increased ARv7 expression can transcriptionally enhance MAO-A expression resulting in Enz resistance via altering the hypoxia HIF-1α signals. Together, our results show that targeting the Enz/ARv7/MAO-A signaling with the antidepressants phenelzine or clorgyline can restore Enz sensitivity to suppress EnzR cell growth, which may indicate that these antidepression drugs can overcome the Enz resistance to further suppress the EnzR CRPC.
- 17 May 2019
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 40  (6) , 776-784
Usefulness of a Novel System for Feedback of Patient-Reported Outcome Measures in Children Recovering From Burns
The Burn Outcomes Questionnaire for children ages 5-18 years (BOQ5-18) is a widely used, reliable, and valid parent-reported outcome measure designed to assess children’s recovery from burn injuries in twelve physical and psychosocial domains. This study evaluated the feasibility, acceptability, and usefulness of a feedback system that delivered BOQ and Pediatric Symptom Checklist (PSC-17; a widely used measure of psychosocial functioning) results to burn care clinicians prior to an outpatient appointment or a postoperative surgical encounter. The BOQ and the PSC-17 were administered to the parents of 147 children receiving outpatient or surgical care in two pediatric burn hospitals. Clinician and parent perceptions of the feedback system were evaluated using debriefing questionnaires. Over half of all patients were at-risk on at least one BOQ subscale, and risk on three or more BOQ domains was significantly associated with a higher likelihood of poor psychological scores on the PSC-17 (p<.001). Significant differences in BOQ scores were found between the two hospital sites on four BOQ subscales, three related to physical ability and one to psychosocial wellbeing. Parent ratings of the feedback system were positive, with 90% of parents in both settings agreeing that the BOQ tablet experience was easy and helpful. Clinician attitudes differed across the two settings with more positive clinician ratings of the system in the outpatient setting (p<.001). Clinician interviews revealed that the data was especially useful in bringing to light psychosocial aspects of functioning relevant to long-term recovery from burn injuries.
- 17 May 2019
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 40  (6) , 776-784
Usefulness of a Novel System for Feedback of Patient-Reported Outcome Measures in Children Recovering From Burns
The Burn Outcomes Questionnaire for children ages 5-18 years (BOQ5-18) is a widely used, reliable, and valid parent-reported outcome measure designed to assess children’s recovery from burn injuries in twelve physical and psychosocial domains. This study evaluated the feasibility, acceptability, and usefulness of a feedback system that delivered BOQ and Pediatric Symptom Checklist (PSC-17; a widely used measure of psychosocial functioning) results to burn care clinicians prior to an outpatient appointment or a postoperative surgical encounter. The BOQ and the PSC-17 were administered to the parents of 147 children receiving outpatient or surgical care in two pediatric burn hospitals. Clinician and parent perceptions of the feedback system were evaluated using debriefing questionnaires. Over half of all patients were at-risk on at least one BOQ subscale, and risk on three or more BOQ domains was significantly associated with a higher likelihood of poor psychological scores on the PSC-17 (p<.001). Significant differences in BOQ scores were found between the two hospital sites on four BOQ subscales, three related to physical ability and one to psychosocial wellbeing. Parent ratings of the feedback system were positive, with 90% of parents in both settings agreeing that the BOQ tablet experience was easy and helpful. Clinician attitudes differed across the two settings with more positive clinician ratings of the system in the outpatient setting (p<.001). Clinician interviews revealed that the data was especially useful in bringing to light psychosocial aspects of functioning relevant to long-term recovery from burn injuries.
- 1 December 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49  (12) , 2866-2871
The 2CAN Score
Background and Purpose—: A quarter of acute strokes occur in patients hospitalized for another reason. A stroke recognition instrument may be useful for non-neurologists to discern strokes from mimics such as seizures or delirium. We aimed to derive and validate a clinical score to distinguish stroke from mimics among inhospital suspected strokes. Methods—: We reviewed consecutive inpatient stroke alerts in a single academic center from January 9, 2014, to December 7, 2016. Data points, including demographics, stroke risk factors, stroke alert reason, postoperative status, neurological examination, vital signs and laboratory values, and final diagnosis, were collected. Using multivariate logistic regression, we derived a weighted scoring system in the first half of patients (derivation cohort) and validated it in the remaining half of patients (validation cohort) using receiver operating characteristics testing. Results—: Among 330 subjects, 116 (35.2%) had confirmed stroke, 43 (13.0%) had a neurological mimic (eg, seizure), and 171 (51.8%) had a non-neurological mimic (eg, encephalopathy). Four risk factors independently predicted stroke: clinical deficit score (clinical deficit score 1: 1 point; clinical deficit score ≥2: 3 points), recent cardiac procedure (1 point), history of atrial fibrillation (1 point), and being a new patient (<24 hours from admission: 1 point). The score showed excellent discrimination in the first 165 patients (derivation cohort, area under the curve=0.93) and remaining 165 patients (validation cohort, area under the curve=0.88). A score of ≥2 had 92.2% sensitivity, 69.6% specificity, 62.2% positive predictive value, and 94.3% negative predictive value for identifying stroke. Conclusions—: The 2CAN score for recognizing inpatient stroke performs well in a single-center study. A future prospective multicenter study would help validate this score.
- 1 December 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49  (12) , 2866-2871
The 2CAN Score
Background and Purpose—: A quarter of acute strokes occur in patients hospitalized for another reason. A stroke recognition instrument may be useful for non-neurologists to discern strokes from mimics such as seizures or delirium. We aimed to derive and validate a clinical score to distinguish stroke from mimics among inhospital suspected strokes. Methods—: We reviewed consecutive inpatient stroke alerts in a single academic center from January 9, 2014, to December 7, 2016. Data points, including demographics, stroke risk factors, stroke alert reason, postoperative status, neurological examination, vital signs and laboratory values, and final diagnosis, were collected. Using multivariate logistic regression, we derived a weighted scoring system in the first half of patients (derivation cohort) and validated it in the remaining half of patients (validation cohort) using receiver operating characteristics testing. Results—: Among 330 subjects, 116 (35.2%) had confirmed stroke, 43 (13.0%) had a neurological mimic (eg, seizure), and 171 (51.8%) had a non-neurological mimic (eg, encephalopathy). Four risk factors independently predicted stroke: clinical deficit score (clinical deficit score 1: 1 point; clinical deficit score ≥2: 3 points), recent cardiac procedure (1 point), history of atrial fibrillation (1 point), and being a new patient (<24 hours from admission: 1 point). The score showed excellent discrimination in the first 165 patients (derivation cohort, area under the curve=0.93) and remaining 165 patients (validation cohort, area under the curve=0.88). A score of ≥2 had 92.2% sensitivity, 69.6% specificity, 62.2% positive predictive value, and 94.3% negative predictive value for identifying stroke. Conclusions—: The 2CAN score for recognizing inpatient stroke performs well in a single-center study. A future prospective multicenter study would help validate this score.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49  (Suppl_1)
Abstract 193: The 2CAN Score: A Novel Inpatient Stroke Recognition Instrument
Introduction: A quarter of strokes occur in patients hospitalized for another reason. Inpatient stroke alerts are challenging due to complex medical situations. A stroke recognition instrument may be useful for general practitioners to discern neurologic deficits due to hemorrhagic or ischemic stroke from mimics such as seizures, delirium, and hypoglycemia. Hypothesis: Clinical factors present at the initial evaluation of suspected inpatient stroke patients will distinguish strokes from mimics. Methods: This was a retrospective review of inpatient stroke alerts from 9/1/2014 to 7/31/2016. Final diagnosis of stroke was based on stroke attending documentation and imaging confirmation if available. We evaluated predictors of stroke diagnosis including demographics, stroke risk factors, stroke alert reason, post-operative status and time from admission, NIHSS and CPSS scores abstracted from notes, vital signs, and laboratory values. Using the first 165 patients for derivation and the second 165 for validation, we used univariate and multivariate logistic regression and c-statistics to derive and validate a scoring system to predict stroke diagnosis. Results: Among 394 alerts, 64 were excluded due to incomplete documentation. Of 330 remaining patients, 116 (35.2%) were diagnosed with stroke, 43 (13.0%) had a neurological mimic (e.g., seizure), and 171 (51.8%) had a non-neurologic mimic (e.g., sepsis, drug effect, or delirium). In multivariate analysis in the derivation cohort, we identified 4 independent predictors of inpatient stroke: abnormal CPSS, post- C ardiac procedure, history of A trial fibrillation, and being a N ew (admitted within 24 hours) patient. The 2CAN score gives one point for each positive variable above, with additional 2 points for a CPSS ≥2 for a total score range from 0 to 6. The 2CAN score had c-statistic 0.93 (95% CI 0.88-0.97) in the derivation and 0.88 (95% CI 0.82-0.94) in the validation cohorts, respectively. A 2CAN score ≥2 had 92.2% sensitivity, 69.6% specificity, 62.2% positive predictive value, and 94.3% negative predictive value for identifying stroke. Conclusion: The 2CAN score is a sensitive screening tool for identifying inpatient stroke. Further external and prospective validation of this score is warranted.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49  (Suppl_1)
Abstract 193: The 2CAN Score: A Novel Inpatient Stroke Recognition Instrument
Introduction: A quarter of strokes occur in patients hospitalized for another reason. Inpatient stroke alerts are challenging due to complex medical situations. A stroke recognition instrument may be useful for general practitioners to discern neurologic deficits due to hemorrhagic or ischemic stroke from mimics such as seizures, delirium, and hypoglycemia. Hypothesis: Clinical factors present at the initial evaluation of suspected inpatient stroke patients will distinguish strokes from mimics. Methods: This was a retrospective review of inpatient stroke alerts from 9/1/2014 to 7/31/2016. Final diagnosis of stroke was based on stroke attending documentation and imaging confirmation if available. We evaluated predictors of stroke diagnosis including demographics, stroke risk factors, stroke alert reason, post-operative status and time from admission, NIHSS and CPSS scores abstracted from notes, vital signs, and laboratory values. Using the first 165 patients for derivation and the second 165 for validation, we used univariate and multivariate logistic regression and c-statistics to derive and validate a scoring system to predict stroke diagnosis. Results: Among 394 alerts, 64 were excluded due to incomplete documentation. Of 330 remaining patients, 116 (35.2%) were diagnosed with stroke, 43 (13.0%) had a neurological mimic (e.g., seizure), and 171 (51.8%) had a non-neurologic mimic (e.g., sepsis, drug effect, or delirium). In multivariate analysis in the derivation cohort, we identified 4 independent predictors of inpatient stroke: abnormal CPSS, post- C ardiac procedure, history of A trial fibrillation, and being a N ew (admitted within 24 hours) patient. The 2CAN score gives one point for each positive variable above, with additional 2 points for a CPSS ≥2 for a total score range from 0 to 6. The 2CAN score had c-statistic 0.93 (95% CI 0.88-0.97) in the derivation and 0.88 (95% CI 0.82-0.94) in the validation cohorts, respectively. A 2CAN score ≥2 had 92.2% sensitivity, 69.6% specificity, 62.2% positive predictive value, and 94.3% negative predictive value for identifying stroke. Conclusion: The 2CAN score is a sensitive screening tool for identifying inpatient stroke. Further external and prospective validation of this score is warranted.
- Open Access
- 13 April 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 484
Recent advances in the management of acute ischemic stroke
In recent years, several landmark trials have transformed acute ischemic stroke care. The most dramatic results from the field of acute endovascular intervention demonstrate unequivocal benefit for a select group of patients with moderate to severe deficits presenting within 7 hours from onset and with occlusions of proximal arteries in the anterior circulation. In addition, technological advances and workflow efficiencies have facilitated more rapid delivery of acute stroke interventions. This review provides an overview of recent advances in the management of acute ischemic stroke.
- 13 April 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 484
Open AccessRecent advances in the management of acute ischemic stroke
In recent years, several landmark trials have transformed acute ischemic stroke care. The most dramatic results from the field of acute endovascular intervention demonstrate unequivocal benefit for a select group of patients with moderate to severe deficits presenting within 7 hours from onset and with occlusions of proximal arteries in the anterior circulation. In addition, technological advances and workflow efficiencies have facilitated more rapid delivery of acute stroke interventions. This review provides an overview of recent advances in the management of acute ischemic stroke.
- Open Access
- 1 January 2014
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 35  (4) , 349-353
A Simple Cost-Saving Measure
The optimal concentration of mafenide acetate solution for use in the treatment of burns is unknown. Despite data supporting the use of a 2.5% solution, 5% formulation is traditionally used, and has been the highest-costing medication on formulary. The aim of the current study is to evaluate cost and patient outcomes associated with a new policy implementing the use of 2.5% solution in burn patients and restricting the 5% formulation to specific indications only. A retrospective review of all patients receiving mafenide acetate solution at a single pediatric burn hospital was performed before and after the initiation of the new policy on the use of 5 vs 2.5% solution. Duration of therapy, adverse events, cost, incidence of wound infection, and bacteremia were analyzed. In 2009, 69 patients were treated with 5% mafenide acetate solution for a total cost of $125,000 ($1811 per patient). In 2010, after the initiation of the policy, 48 patients were treated: 19 received 5% mafenide acetate solution with appropriate indication, whereas the remaining 29 received 2.5% solution for a total cost of $38,632 ($804 per patient). There were no significant changes in the incidence of bacteremia or wound infection. No side effects of either solution were noted. Under certain conditions, a 2.5% mafenide acetate solution appears sufficient. In this multinational pediatric burn hospital, the use of a 2.5% solution was not associated with increased bacteremia or wound infection, and proved to be more cost-effective.
- 1 January 2014
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 35  (4) , 349-353
Open AccessA Simple Cost-Saving Measure
The optimal concentration of mafenide acetate solution for use in the treatment of burns is unknown. Despite data supporting the use of a 2.5% solution, 5% formulation is traditionally used, and has been the highest-costing medication on formulary. The aim of the current study is to evaluate cost and patient outcomes associated with a new policy implementing the use of 2.5% solution in burn patients and restricting the 5% formulation to specific indications only. A retrospective review of all patients receiving mafenide acetate solution at a single pediatric burn hospital was performed before and after the initiation of the new policy on the use of 5 vs 2.5% solution. Duration of therapy, adverse events, cost, incidence of wound infection, and bacteremia were analyzed. In 2009, 69 patients were treated with 5% mafenide acetate solution for a total cost of $125,000 ($1811 per patient). In 2010, after the initiation of the policy, 48 patients were treated: 19 received 5% mafenide acetate solution with appropriate indication, whereas the remaining 29 received 2.5% solution for a total cost of $38,632 ($804 per patient). There were no significant changes in the incidence of bacteremia or wound infection. No side effects of either solution were noted. Under certain conditions, a 2.5% mafenide acetate solution appears sufficient. In this multinational pediatric burn hospital, the use of a 2.5% solution was not associated with increased bacteremia or wound infection, and proved to be more cost-effective.
- 31 October 2012
- Published by Elsevier in Academic Radiology
- Vol. 19  (10) , 1181-1185
Comparison of the Sensitivity of a Pre-MRI Questionnaire and Point of Care eGFR Testing for Detection of Impaired Renal Function
- 31 October 2012
- Published by Elsevier in Academic Radiology
- Vol. 19  (10) , 1181-1185
Comparison of the Sensitivity of a Pre-MRI Questionnaire and Point of Care eGFR Testing for Detection of Impaired Renal Function
- 25 July 2012
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 304  (7) , 499-510
The role of androgen and androgen receptor in skin-related disorders
Androgen and androgen receptor (AR) may play important roles in several skin-related diseases, such as androgenetic alopecia and acne vulgaris. Current treatments for these androgen/AR-involved diseases, which target the synthesis of androgens or prevent its binding to AR, can cause significant adverse side effects. Based on the recent studies using AR knockout mice, it has been suggested that AR and androgens play distinct roles in the skin pathogenesis, and AR seems to be a better target than androgens for the treatment of these skin diseases. Here, we review recent studies of androgen/AR roles in several skin-related disorders, including acne vulgaris, androgenetic alopecia and hirsutism, as well as cutaneous wound healing.
- 25 July 2012
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 304  (7) , 499-510
The role of androgen and androgen receptor in skin-related disorders
Androgen and androgen receptor (AR) may play important roles in several skin-related diseases, such as androgenetic alopecia and acne vulgaris. Current treatments for these androgen/AR-involved diseases, which target the synthesis of androgens or prevent its binding to AR, can cause significant adverse side effects. Based on the recent studies using AR knockout mice, it has been suggested that AR and androgens play distinct roles in the skin pathogenesis, and AR seems to be a better target than androgens for the treatment of these skin diseases. Here, we review recent studies of androgen/AR roles in several skin-related disorders, including acne vulgaris, androgenetic alopecia and hirsutism, as well as cutaneous wound healing.
- Open Access
- 1 December 2009
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 119  (12) , 3739-3751
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expression
Cutaneous wounds heal more slowly in elderly males than in elderly females, suggesting a role for sex hormones in the healing process. Indeed, androgen/androgen receptor (AR) signaling has been shown to inhibit cutaneous wound healing. AR is expressed in several cell types in healing skin, including keratinocytes, dermal fibroblasts, and infiltrating macrophages, but the exact role of androgen/AR signaling in these different cell types remains unclear. To address this question, we generated and studied cutaneous wound healing in cell-specific AR knockout (ARKO) mice. General and myeloid-specific ARKO mice exhibited accelerated wound healing compared with WT mice, whereas keratinocyte- and fibroblast-specific ARKO mice did not. Importantly, the rate of wound healing in the general ARKO mice was dependent on AR and not serum androgen levels. Interestingly, although dispensable for wound closure, keratinocyte AR promoted re-epithelialization, while fibroblast AR suppressed it. Further analysis indicated that AR suppressed wound healing by enhancing the inflammatory response through a localized increase in TNF-α expression. Furthermore, AR enhanced local TNF-α expression via multiple mechanisms, including increasing the inflammatory monocyte population, enhancing monocyte chemotaxis by upregulating CCR2 expression, and enhancing TNF-α expression in macrophages. Finally, targeting AR by topical application of a compound (ASC-J9) that degrades AR protein resulted in accelerated healing, suggesting a potential new therapeutic approach that may lead to better treatment of wound healing.
- 1 December 2009
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 119  (12) , 3739-3751
Open AccessMonocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expression
Cutaneous wounds heal more slowly in elderly males than in elderly females, suggesting a role for sex hormones in the healing process. Indeed, androgen/androgen receptor (AR) signaling has been shown to inhibit cutaneous wound healing. AR is expressed in several cell types in healing skin, including keratinocytes, dermal fibroblasts, and infiltrating macrophages, but the exact role of androgen/AR signaling in these different cell types remains unclear. To address this question, we generated and studied cutaneous wound healing in cell-specific AR knockout (ARKO) mice. General and myeloid-specific ARKO mice exhibited accelerated wound healing compared with WT mice, whereas keratinocyte- and fibroblast-specific ARKO mice did not. Importantly, the rate of wound healing in the general ARKO mice was dependent on AR and not serum androgen levels. Interestingly, although dispensable for wound closure, keratinocyte AR promoted re-epithelialization, while fibroblast AR suppressed it. Further analysis indicated that AR suppressed wound healing by enhancing the inflammatory response through a localized increase in TNF-α expression. Furthermore, AR enhanced local TNF-α expression via multiple mechanisms, including increasing the inflammatory monocyte population, enhancing monocyte chemotaxis by upregulating CCR2 expression, and enhancing TNF-α expression in macrophages. Finally, targeting AR by topical application of a compound (ASC-J9) that degrades AR protein resulted in accelerated healing, suggesting a potential new therapeutic approach that may lead to better treatment of wound healing.